Abstract:Summary Background An Escherichia coli -produced human papillomavirus (HPV) 16 and 18 bivalent vaccine (Cecolin) was prequalified by WHO in 2021. This study aimed to compare the immunogenicity of the E coli -produced HPV 9-valent vaccine Cecolin 9 (against HPV 6 , 11, 16, 18, 31, 33, 45, 52, and 58) with Gardasil 9. Methods This was a randomised, single-blind trial conducted in China. Healthy non-pregnant women aged 18–26 years, who were not breastfeeding and with no HPV vaccination history, were enrolled in the Ganyu Centre for Disease Control and Prevention (Lianyungang City, Jiangsu Province, China). Women were stratified by age (18–22 years and 23–26 years) and randomly assigned (1:1) using a permutated block size of eight to receive three doses of Cecolin 9 or Gardasil 9 at day 0, day 45, and month 6. All participants, as well as study personnel without access to the vaccines, were masked. Neutralising antibodies were measured by a triple-colour pseudovirion-based neutralisation assay. The primary outcomes, seroconversion rates and geometric mean concentrations (GMCs) at month 7, were analysed in the per-protocol set for immunogenicity (PPS-I). Non-inferiority was identified for the lower limit of the 95% CI of the GMC ratio (Cecolin 9 vs Gardasil 9) at a margin of 0·5 and a seroconversion rate difference (Cecolin 9–Gardasil 9) at a margin of –5%. This study was registered at ClinicalTrials.gov ( NCT04782895 ) and is completed. Findings From March 14 to 18, 2021, a total of 553 potential participants were screened, of which 244 received at least one dose of Cecolin 9 and 243 received at least one dose of Gardasil 9. The seroconversion rates for all HPV types in both groups were 100% in the PPS-I, with the values of the lower limits of 95% CIs for seroconversion rate differences ranging between –1·8% and –1·7%. The GMC ratios of five types were higher than 1·0, with the highest ratio, for HPV 58 , at 1·65 (95% CI 1·38–1·97), and those of four types were lower than 1·0, with the lowest ratio, for HPV 11, at 0·79 (0·68–0·93). The incidence of adverse reactions in both groups was similar (43% [104/244] vs 47% [115/243]). Interpretation Cecolin 9 induced non-inferior HPV type-specific immune responses compared with Gardasil 9 and is a potential candidate to accelerate the elimination of cervical cancer by allowing for global accessibility to 9-valent HPV vaccinations, especially in low-income and middle-income countries. Funding National Natural Science Foundation, Fujian Provincial Natural Science Foundation, Xiamen Science and Technology Plan Project, Fundamental Research Funds for the Central Universities, CAMS Innovation Fund for Medical Sciences of China, and Xiamen Innovax.

A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials

Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial

Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model

Safety and Immunogenicity of an Escherichia Coli-Produced 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (types 6/11/16/18/31/33/45/52/58) in Healthy Adults: an Open-Label, Dose-Escalation Phase 1 Clinical Trial

Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccine

A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)

Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59

Head-to-head immunogenicity comparison of an Escherichia coli -produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial

Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study

Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine Against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology.

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16-26 years in Chongqing, China

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro

Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine

Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice

Development of a Human Papillomavirus Type 6/11 Vaccine Candidate for the Prevention of Condyloma Acuminatum.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial